Windlas Biotech vs Akums Drugs and Pharmaceuticals: Which Stock Should You Track

Windlas Biotech vs Akums Drugs and Pharmaceuticals is a comparison pharma CDMO investors look up when evaluating two listed contract development and manufacturing organisations for the Indian pharmaceutical industry. Windlas Biotech is a Dehradun-based CDMO specialising in solid oral dosage forms, while Akums Drugs and Pharmaceuticals is one of India's largest CDMO companies supplying formulations to domestic and export customers.

This Windlas Biotech vs Akums Drugs and Pharmaceuticals article covers reach and market position, key products, latest declared results and stock valuation. The Windlas Biotech vs Akums Drugs and Pharmaceuticals data below is sourced from Groww and public company filings and reflects the most recently available information at the time of writing.

Windlas Biotech vs Akums Drugs and Pharmaceuticals: Reach and Market Position

On the Windlas Biotech side of the Windlas Biotech vs Akums Drugs and Pharmaceuticals comparison, Windlas Biotech manufactures solid oral dosage forms including tablets, capsules and sachets for Indian pharma companies and exports. It operates from Dehradun with GMP-compliant facilities. Market capitalisation is Rs 1,792 Cr.

Click Here – Get Free Investment Predictions

On the Akums Drugs and Pharmaceuticals side of the Windlas Biotech vs Akums Drugs and Pharmaceuticals comparison, Akums Drugs and Pharmaceuticals manufactures across tablets, capsules, liquids, injectables and topical formulations for over 1,000 pharma brand companies across India and 30-plus export markets. Market capitalisation is Rs 10,711 Cr.

Windlas Biotech vs Akums Drugs and Pharmaceuticals: Key Products and Business Mix

In the Windlas Biotech vs Akums Drugs and Pharmaceuticals product comparison, Windlas Biotech offers: Windlas Biotech's CDMO services cover product development, scale-up and manufacturing for regulated and domestic market pharma clients. P/E is 26.97x, ROE 11.44 percent, debt to equity 0.06.

For Akums Drugs and Pharmaceuticals in this Windlas Biotech vs Akums Drugs and Pharmaceuticals breakdown: Akums provides pan-formulation CDMO services covering solid, liquid, injectable and topical dosage forms for domestic and export pharma companies. P/E is 41.77x, ROE 7.70 percent, near-zero debt at 0.05.

Windlas Biotech vs Akums Drugs and Pharmaceuticals: Latest Results

The Windlas Biotech vs Akums Drugs and Pharmaceuticals results for Windlas Biotech: Windlas Biotech has a market cap of Rs 1,792 Cr and P/E of 26.97x. ROE is 11.44 percent. It is a smaller, focused CDMO.

The Windlas Biotech vs Akums Drugs and Pharmaceuticals results for Akums Drugs and Pharmaceuticals: Akums Drugs has a market cap of Rs 10,711 Cr and P/E of 41.77x. ROE is 7.70 percent, lower than Windlas despite Akums' larger scale. EPS is Rs 16.29.

Compare Windlas Biotech and Akums Drugs and Pharmaceuticals Fundamentals on the Univest Screener

Windlas Biotech vs Akums Drugs and Pharmaceuticals: Stock and Valuation

The Windlas Biotech vs Akums Drugs and Pharmaceuticals stock comparison uses the latest available market data from Groww. Investors tracking Windlas Biotech vs Akums Drugs and Pharmaceuticals should verify current prices on NSE or BSE before trading.

Windlas Biotech trades at a market cap of Rs 1,792 Cr and P/E of 26.97x, with a higher ROE of 11.44 percent despite its smaller size. Akums Drugs trades at Rs 10,711 Cr market cap and P/E of 41.77x, at a premium valuation. Windlas' higher ROE suggests more capital-efficient operations for its solid oral dosage focus.

Windlas Biotech vs Akums Drugs and Pharmaceuticals: Quick Comparison Table

The Windlas Biotech vs Akums Drugs and Pharmaceuticals comparison table below summarises the key metrics covered in this article side by side.

Parameter	Windlas Biotech	Akums Drugs and Pharmaceuticals
Sector	Pharma CDMO (solid oral dosage)	Pharma CDMO (multi-dosage form)
Market Cap	Rs 1,792 Cr	Rs 10,711 Cr
P/E Ratio	26.97x	41.77x
ROE	11.44%	7.70%
Debt to Equity	0.06	0.05
Dosage forms	Solid oral (tablets, capsules, sachets)	Solid, liquid, injectable, topical
Customer base	Indian pharma companies, export	1,000-plus domestic and 30-plus export markets

Conclusion

The Windlas Biotech vs Akums Drugs and Pharmaceuticals comparison above covers the key data points on reach, products, results and valuation. Windlas Biotech vs Akums Drugs are two pharma CDMO companies serving the Indian pharmaceutical industry's outsourcing needs. Windlas is a focused solid oral specialist with a higher ROE, while Akums is a larger multi-dosage-form platform at a higher valuation. Investors should review order books and capacity utilisation and consult a SEBI-registered advisor before investing.

Download the Univest iOS App or Univest Android App to track Windlas Biotech and Akums Drugs and Pharmaceuticals live price and get daily stock recommendations.

Frequently Asked Questions

What is a pharma CDMO?

Ans. A CDMO (Contract Development and Manufacturing Organisation) manufactures pharmaceutical formulations under contract for brand owners who prefer to outsource production rather than invest in their own plants.

What dosage forms does Akums Drugs make?

Ans. Akums makes tablets, capsules, liquids, injectables and topical formulations across its facilities.

Which company has the higher ROE?

Ans. Windlas Biotech has an ROE of 11.44 percent, above Akums Drugs at 7.70 percent.

Which stock trades at a lower P/E?

Ans. Windlas Biotech trades at 26.97x trailing earnings, lower than Akums Drugs at 41.77x.

Is Akums Drugs an export company?

Ans. Yes. Akums Drugs exports to over 30 countries in addition to its large domestic customer base.

What risks apply to pharma CDMOs?

Ans. Both companies face risk from customer concentration, regulatory compliance costs for GMP facilities, pricing pressure from pharma brand owners and competition from larger global CDMOs.

Should I invest in Windlas Biotech or Akums Drugs?

Ans. This depends on your preference between a focused solid oral specialist with higher ROE and a diversified multi-dosage-form platform. Consult a SEBI-registered advisor before investing.